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Defects of N-linked glycosylation represent diseases with multiple organ involvements that are classiﬁed as
congenital disorders of glycosylation (CDG). In recent years, several CDG types have been attributed to
defects of dolichol-linked oligosaccharide assembly in the endoplasmic reticulum. The proﬁling of
[3H]mannose-labeled lipid-linked oligosaccharides was instrumental in identifying most of these glycosylation
disorders. However, this method is poorly suited for the identiﬁcation of short lipid-linked oligosaccharide
biosynthesis defects. To adequately resolve deﬁciencies affecting the ﬁrst steps of lipid-linked oligosac-
charide formation, we have used a non-radioactive procedure employing the ﬂuorescence detection of
2-aminobenzamide-coupled oligosaccharides after HPLC separation. By applying this method, we have
detected the accumulation of dolichylpyrophosphate-GlcNAc2 in a previously untyped CDG patient. The
accumulation pattern suggested a deﬁciency of the ALG1 b1,4 mannosyltransferase, which adds the
ﬁrst mannose residue to lipid-linked oligosaccharides. This was supported by the ﬁnding that this CDG
patient was compound heterozygous for three mutations in the ALG1 gene, leading to the amino acid
substitutions S150R and D429E on one allele and S258L on the other. The detrimental effect of these mutations
on ALG1 protein function was demonstrated in a complementation assay using alg1 Saccharomyces cerevisiae
yeast mutants. The ALG1 mannosyltransferase defect described here represents a novel type of CDG, which
should be referred to as CDG-Ik.
INTRODUCTION
Inborn errors of glycosylation are a rapidly expanding family of
genetic diseases encompassing various clinical entities.
Deficiencies of N-linked glycosylation, also referred to as
congenital disorders of glycosylation (CDG), represent multi-
systemic diseases with central and peripheral nervous involve-
ments often associated with endocrine and coagulation
disorders (1–3). Defects of O-mannosylation have recently
been associated with Walker–Warburg syndrome (4) and
different forms of muscular dystrophies like Muscle–Eye–
Brain disease (5), Fukuyama congenital muscular dystrophy (6)
and MDC1D (7). Dermatological (8) and bone disorders like
hereditary multiple exostoses (9) are caused by alterations of
glycosaminoglycan chain formation.
The broad symptomatology of glycosylation disorders and
the tremendous structural diversity of glycoconjugates render
the identification of glycosylation defects a difficult task. A
simple test consisting of the isoelectric focusing separation of
serum transferrin (10), a glycoprotein normally bearing two N-
glycan chains, has greatly facilitated the detection of N-linked
glycosylation defects. While this assay reliably identifies
underglycosylation related to lowered sialylation, it lacks the
resolution needed to pinpoint specific enzymatic defects. In
combination with western blot analysis of serum transferrin,
the isoelectric focusing test only allows discrimination between
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defects of oligosaccharide assembly and transfer, defined as
CDG-I (11) and defects of N-linked glycan processing grouped
as CDG-II.
Analysis of [3H]mannose-labeled lipid-linked oligosaccharides
(LLO) has enabled the characterization of several types of CDG-I
caused by alterations of dolichylpyrophosphate (DolPP)-linked
GlcNAc2Man9Glc3 assembly at the membrane of the endoplas-
mic reticulum (ER) (12,13). However, a significant group of
CDG-I patients, diagnosed by serum transferrin analysis, do not
present any accumulation of incomplete oligosaccharides when
using the established LLO profiling method. In fact, this method
lacks the sensitivity required to detect accumulation of short
LLOs such as those lacking mannose or those including only few
mannose units. To remedy this problem, we have adapted a
method based on the fluorescence detection of total cellular LLOs
derivatized with 2-aminobenzamide (2AB). Using this novel
approach, we have screened a group of untyped CDG-I patients
and identified a case characterized by the accumulation ofDolPP-
GlcNAc2. Genetic analysis confirmed in this patient a deficiency
of the ALG1 b1,4 mannosyltransferase, which catalyzes the first
mannosylation step in the assembly of N-glycans.
RESULTS
The male patient FR was born after an uncomplicated
pregnancy and presented early on with minimal signs
of psychomotor development. There were no dysmorphic
features present. The patient was affected by multiple
intractable seizures, generalized muscular hypotonia and
blindness. By 6 months of age, sepsis and pneumonia required
prolonged hospitalization. Before 1 year of age, liver dysfunc-
tion became prominent as well as coagulation problems related
to low antithrombin-III (12% of normal values). MRI scan of
the brain was normal. The combination of developmental
symptoms and coagulation disorder suggested a possible case
of CDG. Isoelectric focusing of serum transferrin showed a
typical CDG-I pattern with decreased tetrasialo and with
increased disialo and asialotransferrin (Fig. 1), thus confirming
the diagnosis. Phosphomannomutase activity measured in the
patient fibroblasts yielded an intermediate value of 2.2mU/mg
protein (normal range 5.3 1.7mU/mg protein), which led to
the sequencing of the candidate PMM2 gene. The patient was
found to be heterozygous for a point mutation causing the
amino acid substitution E197A on the maternal allele. The
PMM2 E197A substitution has been found in combination with
two genuine mutations in three other confirmed CDG-Ia patients.
Hence, it is probably a polymorphism (unpublished data). It was
concluded that it is unrelated to the disease in this patient.
To determine whether a defect of oligosaccharide assembly
was the source of the glycosylation disorder, we analyzed the
LLO profile in the patient fibroblasts after [3H]mannose
labeling using a procedure established previously (14 –16).
This analysis failed to reveal any accumulation of incomplete
LLO structure (Fig. 2A–C). The level of [3H]mannose
incorporation was very low, indicating a limited LLO pool in
the patient’s cells. The detection of newly formed N-linked
oligosaccharides (NLO) after 60min labeling with
[3H]mannose showed the same profile as that found in cells
from healthy controls (Fig. 2D–F), with peaks corresponding to
GlcNAc2Man8, GlcNAc2Man9 and GlcNAc2Man9Glc1. This
result indicated that the fully assembled GlcNAc2Man9Glc3
oligosaccharide was produced in the patient’s cells, although
in limited supply, and was successfully transferred onto
nascent glycoproteins. GlcNAc2Man9 and GlcNAc2Man9Glc1
arise from the trimming by glucosidases-I and -II, while
GlcNAc2Man9Glc1 can also arise from re-glucosylation during
the process of protein folding (17). The GlcNAc2Man8
peak represents the oligosaccharide core trimmed by the ER
a-mannosidase (18).
To support the hypothesis that the conversion of mannose-
1-phosphate to GDP-mannose or to dolichylphosphate-mannose
may be altered, the GDP-mannose pyrophosphorylase GMPPA,
GMPPB genes and the dolichylphosphate-mannose synthase
DPM1, DPM2, DPM3 genes were screened by denaturing-
HPLC (19). No mutation was found in any of these genes, thus
ruling out a shortage of mannose substrates as a cause of the
glycosylation disorder. This conclusion was supported by flow
cytometry analysis where normal levels of the glycosyl-
phosphatidylinositol (GPI)-anchored protein CD59, which also
requires dolichylphosphate-mannose for the synthesis of the
GPI-anchor, were found on the patient fibroblasts (data not
shown).
To enable the detection of short LLOs that have escaped the
established [3H]mannose labeling procedure, we have adapted
the recent method of Gao and Lehrman (20) to allow the
efficient resolution of structures from DolPP-GlcNAc up to
DolPP-GlcNAc2Man9Glc3. Total LLOs were isolated from
fibroblasts and hydrolyzed to liberate the glycan moiety. After a
reductive amination with the fluorophore 2AB at their reducing
termini, oligosaccharides were separated on a GlycoSep-N
HPLC column, permitting the clear resolution of all oligosac-
charide species found in LLOs. In the HPLC profile of patient
FR, one can identify a peak comigrating with the external
standard GlcNAc(b1,4)GlcNAc at 1.73 glucose units as
compared with the elution positions of standard glucose
oligomers (Fig. 3), whereas this peak is not detected in
samples derived from control cells. The identity of this peak
with GlcNAc(b1,4)GlcNAc was further confirmed by running
Figure 1. Isoelectric focusing of serum transferrin. Samples from a healthy
control serum (normal), from a CDG-Ia control and from patient FR are shown.
The number of negative charges is given at the right. The two glycan chains of
normal transferrin contain mainly four sialic acids, whereas bands correspond-
ing to disialo- and asialo-transferrin are visible in the FR sample.
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collected fractions comprising the peak of interest onto a
second dimension of reverse-phase HPLC (data not shown).
This finding suggested an accumulation of DolPP-GlcNAc2 to
be at the origin of the glycosylation disorder in the patient FR.
Also, in the GlycoSep-N HPLC profile of control fibroblasts,
peaks corresponding to GlcNAc2Man9Glc1-3 are visible. These
peaks are also present in the patient HPLC profile, although
with reduced intensity, thus confirming the limited supply of
mature LLOs. The nature of the major peak, following the
elution of chitobiose, is not known. However, after re-
purification of the 2AB-labeled samples, the size of this peak
relative to the chitobiose-peak was clearly reduced, indicative
for non-carbohydrate, labeled material present in both
fibroblast preparations (data not shown).
LLOs are assembled by the stepwise transfer of mono-
saccharides onto DolPP. The accumulation of DolPP-
GlcNAc2 implied a possible defect at the level of the addition
of the first mannose residue catalyzed by the ALG1 b1,4
mannosyltransferase enzyme. The human ALG1 gene has
been characterized recently (21). It encodes a protein of 464
amino acids displaying 36% similarity to the yeast Alg1
enzyme (22). cDNAs encoding homologous proteins were
found in all eukaryotic genomes searched, such as in
Caenorhabditis elegans and in Drosophila melanogaster.
The sequence alignment of the putative ALG1 proteins
showed conserved domains, possibly regions representing
the active site of the enzyme (Fig. 4). The ALG1 cDNA was
amplified by reverse transcription-PCR from control and from
the patient FR fibroblasts. Sequencing of the DNA fragments
revealed three heterozygous point mutations in the ALG1
cDNA of patient FR (Fig. 4). These mutations, 450C>G,
773C>T and 1287T>A, lead to the amino acid substitutions
S150R, S285L and D429E, respectively. These mutations
were not found in control cDNAs sequenced in our
laboratory, nor in 49 ALG1 expressed sequence tags retrieved
from GenBank (data not shown). The 450C>G, 773C>T and
1287T>A mutations detected in the patient FR are located on
exons 4, 7 and 13 of the ALG1 gene, respectively. Sequencing
of these exons in DNA samples isolated from the parents of
the patient FR indicated that the allele with S150R and
D429E was inherited from the mother, whereas the S258L
mutation stemmed from the father. The S258L mutation is
located in a conserved domain of the ALG1 protein. By
contrast, the two maternal mutations do not correspond to
positions conserved in the ALG1 protein of the four species
examined (Fig. 4).
Figure 2. [3H]Mannose-labeled lipid- and N-linked oligosaccharide profiles. HPLC separation of lipid-linked oligosaccharides from yeasts used as standard (A, D),
of control human fibroblasts (B) and of patient FR fibroblasts (C) after metabolic labeling with [3H]mannose for 60min. Oligosaccharides were cleaved from
dolichylpyrophosphate by mild acid hydrolysis and separated by HPLC. The identity of the oligosaccharide peaks ranging from GlcNAc2Man1 (M1)
to GlcNAc2Man9Glc3 (G3) is marked at the top of (A, D). [
3H]Mannose-labeled N-linked oligosaccharides from control cells (E) and from patient FR cells
(F) were separated by HPLC after release from the protein by N-glycosidase F digestion. NLOs with peaks at M8, M9 and G1 are detected in control and patient
fibroblasts.
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To verify that the amino acid changes identified did impair
ALG1 protein function, the ALG1 alleles of the patient FR and
a normal human ALG1 cDNAwere introduced, under control of
the strong glyceraldehyde phosphate dehydrogenase promoter
(23), into S. cerevisiae yeasts carrying the alg1-1 allele. This
mutant allele does not support growth at elevated temperature
due to reduced ALG1 activity (24). As shown in Figure 5,
growth at elevated temperature of the cell was restored by
expressing the wild-type human ALG1 cDNA. By contrast, the
expression of the ALG1 cDNAs isolated in the patient FR did
not enable alg1-1 yeasts to grow to the same extent as when
transformed with the normal human ALG1 cDNA. To examine
the pathological impact of each of the two maternal mutations,
we have transfected alg1-1 yeasts with human ALG1 cDNAs
bearing the single mutation 450C>G [S150R] or the mutation
1287T>A [D429E]. The growth of alg1-1 yeasts expressing
the human ALG1[D429E] was similar to that of yeasts trans-
fected with the wild-type human ALG1 cDNA, indicating that
this mutation likely represents a normal polymorphism. By
comparison, the ALG1 cDNA containing the 450C>G
mutation failed to restore growth of alg1-1 yeasts, which
supports the pathological impact of the maternal S150R
substitution on ALG1 function (Fig. 5). Taken together, this
analysis confirmed the direct relationship between the ALG1
mutations and the glycosylation disorder detected in the patient
FR. Thus, the ALG1 defect reported here represents a novel
type of CDG, which should be referred to as CDG-Ik following
the nomenclature rules established previously (11).
DISCUSSION
A new genetic disorder affecting the first mannose transfer of
dolichol-linked oligosaccharide biosynthesis was identified in
this study. The defects in this disorder are caused by mutations
in the ALG1 b1,4 mannosyltransferase gene. The ALG1 protein
catalyzes the transfer of the first mannose residue onto DolPP-
GlcNAc2 using GDP-mannose as donor substrate. This reaction
takes place at the cytosolic side of the ER membrane, where
dolichol-linked oligosaccharides are assembled to DolPP-
GlcNAc2Man5. The latter is then translocated (‘flipped’) into
the lumen of the ER, in a protein-assisted process which
requires Rft1 protein (25). On the lumenal side, the LLO
assembly continues using dolichylphosphate-based donor
substrates. The presence of the three terminal glucoses on
LLOs is required for recognition by the oligosaccharyltrans-
ferase complex (26), although intermediate oligosaccharide
structures can be transferred to nascent glycoproteins when the
mature LLO is under limited supply. Usually under these condi-
tions underglycosylation of proteins is observed as less sugar-
chains are transferred. Such a transfer of incomplete oligo-
saccharides to proteins has been documented in vivo for
example in yeast alg glycosylation mutants (27) as well as in
CDG patients (28–30). Even though in the case of GlcNAc2
transfer to protein has also been demonstrated in vitro (31) and
in vivo in yeast (32), this occurs very inefficiently as it is a poor
substrate for the oligosaccharyltransferase and, most likely, also
for the flippase. Consequently, defects in GlcNAc2Man5 LLO
assembly are severe and mostly lethal in yeast. The same severe
phenotype can be expected in humans for complete blocks of
LLO biosynthesis up to DolPP-GlcNAc2Man5. Even if transfer
to protein would occur in patient cells, these truncated glycans
are not expected to function properly in the glycan dependent
quality control pathway (17,33). Also structures smaller than
GlcNAc2Man3 would not support formation of complex type
glycans. Therefore, the identification of glycosylation defects
along the LLO cytosolic assembly line presupposes that the
mutations encountered would only partially impair the activity
of the corresponding glycosyltransferase enzymes. Yet, the
resulting clinical manifestations can be quite severe, as
observed in the patient reported in the present study.
Unlike the dolichylphosphate-mannose and -glucose depen-
dent ER glycosyltransferases acting on luminally oriented
LLOs, which are highly hydrophobic proteins with multiple
transmembrane domains, the ALG1 sequence predicts a type-II
transmembrane topology reminiscent of Golgi-localized glyco-
syltransferases. Alignment with homologous proteins in several
eukaryotic species shows strong sequence conservation in the
C-terminal half of ALG1 proteins, suggesting the localization
of the catalytic domain in this part of the protein. This is
supported by significant homology with several prokaryotic
Figure 3. 2-Aminobenzamide-labeled oligosaccharide profiles on GlycoSep-N
HPLC. (A) The separation of standard glucose oligomers with peaks corre-
sponding to Glc1 up to Glc12, i.e. 1–12 glucose units. The external standard
chitobiose (CHB), i.e. GlcNAc(b1,4)GlcNAc, elutes between Glc1 and Glc2
at 1.73 glucose units. The lipid-linked oligosaccharide profiles extracted from
control (B) and patient FR (C) show in the FR sample a peak corresponding
to the elution position of chitobiose, which is not visible in the control profile
as indicated by the arrow.
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glycosyltransferase proteins in eubacteria (Pseudomonas,
Listeria) and archae (Methanosarcina, Methanococcus). The
three mutations identified in the patient FR were not at
positions strictly conserved among ALG1 protein homologs.
This is consistent with a leaky phenotype as the observed
residual activity in the patient fibroblasts enabled the formation
of complete N-glycan chains on glycoproteins.
The ALG1 deficiency represents the third type of
CDG characterized by a defect of a cytosol-oriented
ER-glycosyltransferase besides the ALG2 mannosyltransferase
(34) and ALG7 N-acetylglucosamine-1-phosphotransferase
(35) deficiencies, which have been assigned as CDG-Ii and
-Ij, respectively. In these cases too, mutations lead to partial
inactivation of the enzymes, resulting in low cellular pools of
LLOs but to the transfer of complete oligosaccharides onto
nascent glycoproteins.
For the ALG1 patient studied here, the analysis of LLOs
metabolically labeled with [3H]mannose showed normal
profiles, although with low incorporation yields, as observed
in the cases of ALG2 (34) and ALG7 (35) deficiency described
elsewhere. These findings are readily explained considering the
enzymatic defects leading to the accumulation of LLO species
containing no or at most two tritiated mannoses. Several CDG-I
patients remain untyped because the analysis of LLO profiles
obtained from their fibroblasts only shows low [3H]mannose
incorporation and a peak corresponding to the complete
DolPP-GlcNAc2Man9Glc3 structure. Thus, the efficient detec-
tion of accumulating short LLO structures requires the
establishment of alternative methods. Gao and Lehrman (20)
have recently presented a procedure allowing the quantitative
detection of total LLOs from cell cultures and animal tissues
without metabolic labeling. However, to permit separation and
detection of all LLO structures in a single run, we separated
2AB-derivatized oligosaccharides using a GlycoSep-N HPLC
column. As shown in the present study, this method allows the
quantitative detection of short LLO species without the use of
radioactive isotopes, which was critical for the diagnosis of the
ALG1 mannosyltransferase deficiency. The availability of this
alternative LLO analysis procedure should enable the identi-
fication of further CDG-I types uncharacterizable using
the radioactive method. Besides the medical importance of
establishing a precise diagnostic, the characterization of CDG-I
cases associated with the accumulation of short LLOs may help
identification of still undiscovered glycosyltransferase genes
along the ER-glycosylation pathway. This includes the UDP-
GlcNAc:DolPP-GlcNAc b1,4 N-acetylglucosaminyltransferase
Figure 4. ALG1 protein sequence comparison. Amino acid sequences of ALG1 proteins from Homo sapiens (HsALG1), S. cerevisiae (ScALG1), C. elegans
(CeALG1) and D. melanogaster (DmALG1) were aligned using the ClustalW program. Positions conserved in the four species are shaded in black, conserved
in three species are shaded in gray. The amino acid changes S150R, S258L and D429E in patient FR are indicated above the human ALG1 sequence. The electro-
pherograms representing the corresponding mutations detected in the ALG1 cDNA from patient FR are shown below the alignment. The maternal mutations
S150R, D429E and the paternal S258L mutation are marked with arrows.
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and the GDP-mannose:DolPP-GlcNAc2Man2 a1,6 mannosyl-
transferase genes.
MATERIALS AND METHODS
Glycan extraction
Patient primary fibroblasts were isolated from a skin biopsy and
grown in Dulbecco’s modified Eagle’s medium (DMEM/F12,
Gibco) with 4.5 g/l glucose and 10% fetal calf serum.
Fibroblasts (5 107) were cultured to 90% of confluence and
metabolically labeled with 150mCi [3H]mannose (54.0Ci/mmol,
Amersham Bioscience) as described previously (30). Short
LLOs were extracted twice from the cell pellets with 3ml of
chloroform–methanol 3 : 2 (v/v). Long LLOs were then further
extracted twice with 3ml of chloroform–methanol–water
10 : 10 : 3 (v/v/v). N-linked oligosaccharides (NLOs) were
recovered from the solid cell pellet after LLO extraction by
N-glycosidase F digestion (30).
HPLC analysis of [3H]mannose-labeled oligosaccharides
[3H]Mannose-labeled oligosaccharides were separated on a
250 4.6mmLC-NH2 aminopropyl column (Supelco), equipped
with an LC-NH2 guard column, as described previously (36).
Hydrolysis and cleanup of total cellular LLOs
Total cellular LLOs were extracted from 5 107 fibroblasts as
described above but without metabolic labeling. Dried LLOs
were hydrolyzed with 2ml of 0.1M HCl in 50% isopropyl
alcohol at 50C for 60min to release pyrophosphate-linked
oligosaccharides (20). Hydrolysates were neutralized by adding
1ml of 0.2 M NaOH and residual salt and lipids were removed
by loading the samples onto C18 SepPak columns (Waters)
directly connected to 3ml ENVI-CARB solid phase extraction
tubes (Supelco). These combined columns were conditioned
with 5ml of methanol, followed by 5ml of acetonitrile and 5ml
H2O–acetonitrile (3 : 1, v/v) then equilibrated with 9ml of 2%
acetonitrile/0.1M ammonium acetate in H2O. After loading of
the samples, the columns were washed with 9ml of the same
solution. For elution of the oligosaccharides, the C18 SepPak
cartridge was removed and glycans were eluted from the ENVI-
CARB tube with 6ml of H2O–acetonitrile (3 : 1, v/v).
2-Aminobenzamide labeling of oligosaccharides
and HPLC separation
The dried samples were labeled with 2AB according to Bigge
et al. (37). The glycan cleanup was performed using the paper
disk method as described in Merry et al. (38). The separation of
2AB-labeled N-glycans was performed by HPLC using a
GlycoSep-N column (Glyko Inc.) according to Royle et al. (39)
but modified to a three solvent system suitable for low pressure
gradient mixing. Solvent A was 10mM formic acid adjusted to
pH 4.4 with ammonia solution in 80% acetonitrile. Solvent B
was 30mM formic acid adjusted to pH 4.4 with ammonia
solution in 40% acetonitrile. Solvent C was 0.5% formic acid.
The column temperature was 30C. Gradient conditions were a
linear gradient of 100% A to 100% B over 160min at a flow
rate of 0.4ml/min, followed by 2min 100% B to 100% C,
increasing the flow rate to 1ml/min. The column was washed
for 5min with 100% C, returning to 100% A over 2min and
running for 6min at 100% A at a flow rate of 1ml/min, then
returning the flow rate to 0.4ml/min for 5min. Samples were
injected in water.
Reverse transcription–PCR
RNA was extracted from 2 107 fibroblasts using Tri-reagent
(Sigma) following the instructions of the manufacturer. cDNA
was synthesized from 5mg of total RNA using the specific ALG1
reverse primer 50-AACGCAGGATGAGGAGTTCT-30, with 5%
DMSO and 1 unit of reverse transcriptase ImPromII (Promega).
The synthesis was performed at 42C for 120min. The protein
coding region was amplified by PCR using 3ml of RT product
and the primers 50-ATGGCGGCCTCATGCTTGGT-30 and
50-CCAAGCCTCCAGAGAAGA-30. The cycling conditions
were 30 cycles at 94C for 45 s, 55C for 30 s and 72C for
2min. Primers and unincorporated nucleotides were eliminated
using Qiaquick columns (Qiagen) and the PCR products were
directly sequenced (Microsynth, Balgach, Switzerland).
Genomic DNA PCR
Genomic DNA from patient FR and from his parents was
isolated from 107 fibroblasts and from 5ml of blood,
respectively. ALG1 exons 4, 7 and 13 were amplified with the
primers 50-CCATCACCAGCTGTTGTTAG-30, 50-CAGCATTC-
GGCCTGATTCAC-30, 50-TGGCCTGGTGCTGCTGATGT-30,
50-AGCTGCCAGCAGGATGGAGA-30 and 50-GTGGCTGC-
TTGGCCAGCTTA-30, 50-CGAAGAGCACTTGGAGATG-30,
respectively, for 30 cycles at 94C for 45 s, 54C for 30 s and
72C for 1.5min. The PCR products were directly sequenced
(Microsynth, Balgach, Switzerland) after removal of the primers
and unincorporated nucleotides. The other genes were screened
essentially as described before (19).
Figure 5. Complementation of alg1-1 yeasts with human ALG1 cDNAs.
Transformants were spotted in 10-fold dilutions on YPD plates and incubated
at 23 or 36C for 90 h. Transformation was performed with the vector alone
(mock), the pMJ-ALG1 vector expressing the S. cerevisiae ALG1 gene
(ScALG1) and with plasmids expressing normal human ALG1 cDNA
(HsALG1), the mutated cDNAs from patient FR (HsALG1[S150R, D429E],
HsALG1[S258L]) and ALG1 cDNAs containing the isolated S150R and
D429E mutations.
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Plasmid construction
The human ALG1 cDNAs from healthy control, the S150R/
D429E allele and the S258L allele from patient fibroblasts were
amplified with the primers 50-ACTGCTGCGGAGGATCCAA-
GATGGC-30 and 50-CCAAGCCTCCAGAGAAGA-30, which
contain a BamHI or a HindIII restriction site (underlined). The
fragments were subcloned into the BamHI and HindIII sites of
pBluescript-II SKþ (Stratagene). From there, the human ALG1
cDNAs from patient FR and from control fibroblasts were
subcloned as BamHI–XhoI fragments into p426GDP (40). To
separate the S150R and D429E mutations, 467 bp EcoRI–PaeI
or 58 bp Kpn2I–Bpu1102I fragments of the patient’s S150R/
D429E cDNA were replaced by the corresponding fragments
from normal human ALG1 cDNA. The resulting plasmids are
multicopy yeast vectors with the ALG1 cDNAs under control of
the TDH3 promoter. The plasmid pMJ-ALG1, a single-copy
plasmid with the yeast ALG1 gene under control of its own
promotor, was created from pRS316-NES17 (41) by digestion
with EcoRI followed by self-ligation.
Yeast strains and media
S. cerevisiae strains used in this study were derivatives of K57-6C
(MATa alg1-1 ura3–52 mal gal2 can(r)) (ATCC 208304).
Standard yeast media and genetic techniques were used (42).
Yeast cells were transformed using the LiOAc/PEG method and
the transformants were selected on solid medium lacking uracil.
Strain K57-6C and its transformants were propagated at 23C.
Complementation of ALG1 mutants
Strain K57-6C and its transformants were grown in liquid medium
lacking uracil but supplemented with 1M sorbitol. For the spot
assay, 5ml of serial 10-fold dilutions of K57-6C transformants
were spotted on full medium (YPD), starting at 5 105 cells.
Plates were incubated at a given temperature for 90 h.
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